---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-107275"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:35:13.580861+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Stoke Q2 net loss $23.5M; Phase 3 EMPEROR dosed, 3-year OLE data show durability

## Summary
- Net loss $23.5M ($0.40/sh) for Q2 2025 vs $25.7M loss in Q2 2024; H1 net income $89.4M from Biogen collaboration.
- First patient dosed in global Phase 3 EMPEROR study of zorevunersen for Dravet syndrome; sites active in US, UK, Japan.
- New 3-year OLE data show durable seizure reductions and continued improvements in cognition/behavior.
- Phase 1 OSPREY study of STK-002 initiated for Autosomal Dominant Optic Atrophy (ADOA).
- Cash $355M as of June 30, 2025, expected to fund operations to mid-2028 and into launch readiness.

## SEC filing metadata
- accession: 0000950170-25-107275
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000095017025107275/0000950170-25-107275-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000095017025107275/stok-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-107275
- JSON: https://secwatch.observer/filing/0000950170-25-107275.json
- Plain text: https://secwatch.observer/filing/0000950170-25-107275.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.